Literature DB >> 22887176

Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.

Adam J Olszewski1.   

Abstract

The optimal management of splenic marginal zone lymphoma (SMZL), a rare malignancy of the elderly, is not clearly defined. Splenectomy had been advocated in the past due to its palliative effect on abdominal discomfort, cytopenias, and prolonged remissions, even though most patients have disseminated disease in the bone marrow which subsequently relapses. No prospective studies compared outcomes after surgery or chemotherapy, so the choice of treatment is based on perception of individual benefits and risks. This study analyzed 1,251 cases of SMZL recorded in the Surveillance, Epidemiology, and End Results (SEER) database. Effects of splenectomy on survival outcomes were evaluated after balancing confounders with a propensity score (PS).While 52% of patients underwent spleen removal, no significant impact of the procedure on the risk of lymphoma-related death (LRD) (P 5 0.66)or overall survival was detectable. The results strengthen the notion that, with the availability of safe and effective alternatives, splenectomy should no longer be considered the treatment of choice in SMZL.

Entities:  

Mesh:

Year:  2012        PMID: 22887176     DOI: 10.1002/ajh.23314

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

Review 1.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

Review 2.  Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors:  Sabarish Ayyappan; Basem M William
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

3.  Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region.

Authors:  Shuhua Yi; Yuting Yan; Wenjie Xiong; Rui Lv; Zhen Yu; Wei Liu; Enbin Liu; Heng Li; Huimin Liu; Zengjun Li; Gang An; Yan Xu; Kun Ru; Dehui Zou; Lugui Qiu
Journal:  Oncotarget       Date:  2017-10-19

4.  Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.

Authors:  Gabriela Bastidas-Mora; Sílvia Beà; Alba Navarro; Eva Gine; Dolors Costa; Julio Delgado; Tycho Baumann; Laura Magnano; Alfredo Rivas-Delgado; Neus Villamor; Dolors Colomer; Mónica Lopez-Guerra; María Rozman; Olga Balagué; Daniel Martínez; Maria Joao Baptista; Lourdes Escoda; Miguel Alcoceba; Margarita Blanes; Fina Climent; Elías Campo; Andrew Wotherspoon; Armando López-Guillermo; Estella Matutes
Journal:  Br J Haematol       Date:  2021-09-14       Impact factor: 8.615

5.  A rare case of splenic marginal zone B-cell lymphoma mimicking relapsing polychondritis of the ear.

Authors:  Gary J Huang; Bryan Mendes; Kianoush Sheykholeslami
Journal:  Case Rep Otolaryngol       Date:  2014-12-02

Review 6.  Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.

Authors:  Nathan M Denlinger; Narendranath Epperla; Basem M William
Journal:  Cancer Manag Res       Date:  2018-03-27       Impact factor: 3.989

7.  Splenic marginal cell lymphoma (SMZL): report of its presentation with spontaneous rupture of the spleen.

Authors:  Malcolm C Aldridge; Camilla Nederstrom; Rajiv Swamy
Journal:  J Surg Case Rep       Date:  2013-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.